The Use of Metformin in Early Breast Cancer Patients Pre-Surgery
NCT ID: NCT01302002
Last Updated: 2016-02-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
EARLY_PHASE1
INTERVENTIONAL
2011-01-31
2016-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk
NCT02028221
Studying Changes in Breast Density in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride or Placebo on CAN-NCIC-MA.32
NCT01666171
The Effect of Metformin on Breast Cancer Patients
NCT04559308
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
NCT01286233
Comparison of Healthy Diets on Breast Cancer Markers
NCT02744079
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will collect and analyze pre- and post-treatment blood specimens for:
* Serum glucose
* Insulin levels
* Estradiol
* HOMA test
* Glycosylated haemoglobin
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metformin Pre-Surgery
Patients will take metformin twice a day for three weeks prior surgery
Metformin Pre-Surgery
500 mg tablet, taken twice a day for 3 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Metformin Pre-Surgery
500 mg tablet, taken twice a day for 3 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Knowledge of the investigational nature of the study and ability to provide consent for study participation
Exclusion Criteria
* Recent use of corticosteroids
* AST \> 1.5 times upper limit of normal for the institution
* Pregnancy
* Serious clinical illness
* Prior or concurrent systemic neoadjuvant Breast Cancer therapy.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto Nacional de Cancer, Brazil
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ana Elisa Lohmann
Medical Oncologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ana Elisa Lohmann, MD
Role: PRINCIPAL_INVESTIGATOR
Instituto Nacional de Cancer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital do Cancer III
Rio de Janeiro, Rio de Janeiro, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INCA113/10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.